Strolll Secures £10.35m to Advance Neurorehabilitation Solutions
In an era where technology meets healthcare, revolutionary innovations are changing the way we approach neurorehabilitation. Strolll, a trailblazing digital therapeutic software company, has just announced its success in securing a substantial £10.35m in Series A funding, led by the esteemed IW Capital. This investment not only highlights the emerging potential of augmented reality (AR) in healthcare but also sets Strolll on a transformative path to enhance treatments for patients with neurological disorders such as Parkinson’s disease, stroke, and Multiple Sclerosis.
Strolll stands out in the neurorehabilitation landscape with the introduction of the world’s first clinically validated software platform that integrates AR technology.
By utilizing off-the-shelf AR glasses, the Strolll platform allows patients to engage in gamified rehabilitation exercises both at home and in clinical settings. This dual approach ensures a higher dosage of therapy — up to seven times more treatments delivered with 67% less clinician involvement. The impressive results from clinical trials have shown significant improvements in patient mobility and treatment adherence, with users reporting an astounding 104% adherence rate to the therapy provided via Strolll’s innovative system.
With the newfound funding, Strolll is geared up to catapult its sales and marketing efforts, expand into adjacent neuro-related disorders, and push forward its rigorous regulatory processes. As the global population ages, the increasing prevalence of neurological conditions presents a daunting challenge for healthcare systems worldwide. Investors looking for promising opportunities in the healthcare sector should take note: Strolll's partnership with leading institutions, including a £2.4 million project grant with the University of Leeds and a significant collaboration with Cleveland Clinic in the U.S., positions the company at the forefront of a rapidly growing AR market, projected to expand at a staggering CAGR of 42.6% in the healthcare segment alone by 2030.
Key Terms Explained
- Series A funding
- It's the first significant round of business financing by private equity investors or venture capitalists. In this context, Strolll has secured £10.35 million in Series A funding, providing the financial support for the startup to grow and expand.
- Augmented Reality (AR) in healthcare
- AR refers to the technology that overlays digital information onto the real world. In the healthcare sector, it offers potential for improved diagnosis, treatment and patient care. Here, the startup uses AR for gamified neurorehabilitation exercises.
- CAGR
- Compound Annual Growth Rate, a mean annual growth rate of an investment over a specified period longer than one year. It represents the projected growth of the AR market in the healthcare segment.
Frequently Asked Questions
- What is the amount of funding Strolll secured in Series A?-Strolll secured a substantial £10.35m in Series A funding.
- Who led the Series A funding for Strolll?+
- What is the primary use of the investment Strolll has secured?+
- What are some promising opportunities for investors in the healthcare sector?+
- How does Strolll utilize AR technology for neurorehabilitation?+
They've invested in Strolll
Get to know these AR/VR investors
Click here for a full list of 7,526+ startup investors in the UK